Related Experiment Video
Updated: Mar 13, 2026

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
Published on: January 7, 2019
Ketamine for comorbid treatment-resistant depression and substance use disorders: balancing risks and opportunities
Benjamin D Brody1,2, Dora Kanellopoulos3,4
1Weill Cornell Medicine, Department of Psychiatry, 525 E. 68th Street, New York, NY, 10075, USA. jeb9083@med.cornell.edu.
Abstract:
Recent retrospective analyses have shown that individuals with comorbid Substance Use Disorders (SUDs) are overrepresented among responders to ketamine for Treatment Resistant Depression (TRD). Ketamine is an effective treatment for depression and also a potential substance of misuse. The authors contrast a mechanistic pathway with a possible expectancy effect to account for these findings, and urge careful consideration of risks and benefits when considering ketamine for individuals with TRD and SUDs.
Related Concept Videos
Antidepressant Drugs: MAOIs and Other Agents
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Electroconvulsive Therapy
Psychosis: Goals of Pharmacotherapy
CNS Depressants: Barbiturates and Benzodiazepines
Parenteral Anesthetics: Overview

